264 related articles for article (PubMed ID: 36891151)
21. Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment.
Hoffman-Luca CG; Yang CY; Lu J; Ziazadeh D; McEachern D; Debussche L; Wang S
PLoS One; 2015; 10(6):e0128807. PubMed ID: 26070072
[TBL] [Abstract][Full Text] [Related]
22. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
23. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
[TBL] [Abstract][Full Text] [Related]
24. Mutated p53 protein expression and proliferative activity in advanced gastric cancer.
Ikeguchi M; Saito H; Kondo A; Tsujitani S; Maeta M; Kaibara N
Hepatogastroenterology; 1999; 46(28):2648-53. PubMed ID: 10522058
[TBL] [Abstract][Full Text] [Related]
25. Lung cancer stem cells, p53 mutations and MDM2.
Gadepalli VS; Deb SP; Deb S; Rao RR
Subcell Biochem; 2014; 85():359-70. PubMed ID: 25201204
[TBL] [Abstract][Full Text] [Related]
26. Tetramer formation of tumor suppressor protein p53: Structure, function, and applications.
Kamada R; Toguchi Y; Nomura T; Imagawa T; Sakaguchi K
Biopolymers; 2016 Nov; 106(4):598-612. PubMed ID: 26572807
[TBL] [Abstract][Full Text] [Related]
27. Tumor suppressor p53 and its gain-of-function mutants in cancer.
Liu J; Zhang C; Feng Z
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):170-9. PubMed ID: 24374774
[TBL] [Abstract][Full Text] [Related]
28. Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses.
Lee JH; Byun DS; Lee MG; Ryu BK; Kang MJ; Chae KS; Lee KY; Kim HJ; Park H; Chi SG
Int J Cancer; 2008 Apr; 122(7):1573-84. PubMed ID: 18059034
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
Wang HQ; Mulford IJ; Sharp F; Liang J; Kurtulus S; Trabucco G; Quinn DS; Longmire TA; Patel N; Patil R; Shirley MD; Chen Y; Wang H; Ruddy DA; Fabre C; Williams JA; Hammerman PS; Mataraza J; Platzer B; Halilovic E
Cancer Res; 2021 Jun; 81(11):3079-3091. PubMed ID: 33504557
[TBL] [Abstract][Full Text] [Related]
30. Mutated p53 in HGSC-From a Common Mutation to a Target for Therapy.
Saleh A; Perets R
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298679
[TBL] [Abstract][Full Text] [Related]
31. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
32. The p53 Pathway in Glioblastoma.
Zhang Y; Dube C; Gibert M; Cruickshanks N; Wang B; Coughlan M; Yang Y; Setiady I; Deveau C; Saoud K; Grello C; Oxford M; Yuan F; Abounader R
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30200436
[TBL] [Abstract][Full Text] [Related]
33. The TP53 fertility network.
Paskulin Dd; Paixão-Côrtes VR; Hainaut P; Bortolini MC; Ashton-Prolla P
Genet Mol Biol; 2012 Dec; 35(4 (suppl)):939-46. PubMed ID: 23412905
[TBL] [Abstract][Full Text] [Related]
34. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.
Greiner TC; Dasgupta C; Ho VV; Weisenburger DD; Smith LM; Lynch JC; Vose JM; Fu K; Armitage JO; Braziel RM; Campo E; Delabie J; Gascoyne RD; Jaffe ES; Muller-Hermelink HK; Ott G; Rosenwald A; Staudt LM; Im MY; Karaman MW; Pike BL; Chan WC; Hacia JG
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2352-7. PubMed ID: 16461462
[TBL] [Abstract][Full Text] [Related]
35. Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma.
Li Y; Zhao ZG; Luo Y; Cui H; Wang HY; Jia YF; Gao YT
World J Gastroenterol; 2020 Aug; 26(32):4786-4801. PubMed ID: 32921957
[TBL] [Abstract][Full Text] [Related]
36. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.
Rowan S; Ludwig RL; Haupt Y; Bates S; Lu X; Oren M; Vousden KH
EMBO J; 1996 Feb; 15(4):827-38. PubMed ID: 8631304
[TBL] [Abstract][Full Text] [Related]
37. p53: Protection against Tumor Growth beyond Effects on Cell Cycle and Apoptosis.
Wang X; Simpson ER; Brown KA
Cancer Res; 2015 Dec; 75(23):5001-7. PubMed ID: 26573797
[TBL] [Abstract][Full Text] [Related]
38. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
39. Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion.
Kadioglu O; Saeed M; Mahmoud N; Azawi S; Mrasek K; Liehr T; Efferth T
Arch Toxicol; 2021 Mar; 95(3):959-974. PubMed ID: 33515271
[TBL] [Abstract][Full Text] [Related]
40. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
